BREAKING NEWS
PR Releases
Presented by
Source: AMGEN  Jul 09, 2019
Amgen announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive acute lymphoblastic leukemia (ALL). The study found that with a median follow-up of 59.8 months, the median OS for BLINCYTO-treated patients was 36.5 months (95 percent CI: 22 months - n...
Source: Novartis  May 01, 2019
  Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan Agreement is third announced biosimilars collaboration for San...
Source: Thermo Fisher Scientific  Apr 17, 2019
Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific CEDIA Mitragynine (Kratom) Assay, its newest drugs of abuse test that includes supporting calibrators and controls. The CEDIA Mitragynine (Kratom) Assay can be run on commonly used clinical chemistry analyzers, allowing a broad spectrum of laboratorians to test for the presenc...
Source: Allergan  Mar 11, 2019
- Ubrogepant Seeks to be the First Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for the Acute Treatment of Migraine - - Allergan Continues to Expand Its Leading Migraine Portfolio Across the Spectrum of the Disease from Episodic to Chronic –   March 11, 2019  Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) ha...
Takeda Pharmaceutical Company   Feb 15, 2019
– ADCETRIS in Combination with AVD (Adriamycin, Vinblastine and Dacarbazine) Demonstrated 29-Percent Reduction in the Risk of Progression, Death or Need for Additional Anticancer Therapy for CD30+ Stage IV Patients   – Milestone Marks Fifth Approved Indication for ADCETRIS in Europe, Reinforcing Takeda’s Commitment to Developing Innovative Solutions for People Li...